Phase 3 Clinical Trials With Primary Completion Dates in January 2022
This is a list of Phase 3 trials with primary completion dates in January 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ADIL||Adial Pharmaceuticals, Inc.||2022-01-01||Phase 3||NCT04101227||Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms|
|ARNA||Arena Pharmaceuticals, Inc.||2022-01-01||Phase 3||NCT03945188||Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis|
|CHHE||China Health Industries Holdings, Inc.||2022-01-01||Phase 3||NCT05159947||SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial|
|CORT||Corcept Therapeutics Incorporated||2022-01-01||Phase 3||NCT04329949||Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma|
|CYDY||CytoDyn Inc.||2022-01-01||Phase 3||NCT04901676||Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia|
|FGEN||FibroGen, Inc.||2022-01-01||Phase 3||NCT03263091||Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden|
|MRNS||Marinus Pharmaceuticals, Inc.||2022-01-01||Phase 3||NCT04391569||RAndomized Therapy In Status Epilepticus|
|OBSV||ObsEva SA||2022-01-01||Phase 3||NCT03992846||Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.|
|VRNA||Verona Pharma plc||2022-01-01||Phase 3||NCT04542057||A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD|
|ZGNX||Zogenix, Inc.||2022-01-01||Phase 3||NCT02823145||An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome|